Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2023
07 sept. 2023 16h05 HE
|
Avid Bioservices, Inc
-- Recorded First Quarter Revenue of $37.7 Million -- -- Signed $36 Million in Net New Business Orders Resulting in a Backlog of $189 Million -- -- Cell and Gene Therapy Facility Expansion Remains...
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2024 After Market Close on September 7, 2023
31 août 2023 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2023
21 juin 2023 16h07 HE
|
Avid Bioservices, Inc
-- Fourth Quarter and Full Year Revenue of $39.8 Million and $149.3 Million, Respectively, Both Represent a Record-High Achievement -- -- Signed $55 Million in Net New Business Orders Resulting in a...
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2023 After Market Close on June 21, 2023
14 juin 2023 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices to Participate in RBC Capital Markets Global Healthcare Conference
10 mai 2023 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Unveils Completed Mammalian Cell Facilities Expansion Providing Significantly Increased Capacity for Existing and Future Customers
04 avr. 2023 08h05 HE
|
Avid Bioservices, Inc
Company to Host Open House to Celebrate Official Launch of Newest CGMP Mammalian Cell Manufacturing Suites within Myford Facility First Customer Project in Newly Expanded Capacity to Kick-Off This...
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2023, and Recent Developments
13 mars 2023 16h05 HE
|
Avid Bioservices, Inc
-- Recorded Third Quarter Revenue of $38.0 Million, a 21% Increase Compared to Prior Year Quarter -- -- Signed $67 Million in Net New Business Orders Resulting in a Backlog of $176 million, an...
Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2023 After Market Close on March 13, 2023
06 mars 2023 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2022 and Recent Developments
06 déc. 2022 16h05 HE
|
Avid Bioservices, Inc
-- Recorded Second Quarter Revenue of $34.8 Million -- -- Signed $26 Million in Net New Business Orders Resulting in a Backlog of $147 Million, an Increase of 23% Year-Over-Year -- -- Mammalian...
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2023 After Market Close on December 6, 2022
29 nov. 2022 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...